Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03331250 · ClinicalTrials.gov registry record · Phase 2
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
A Phase 2 study of Angiosarcoma and Epithelioid Hemangioendothelioma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 2
- Study locations
NCT03331250: Active Phase 2 study of Angiosarcoma and Epithelioid Hemangioendothelioma, sponsored by Massachusetts General Hospital.
NCT03331250 is a Phase 2 study of Angiosarcoma and Epithelioid Hemangioendothelioma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 13 participants, below the 1,092-participant average among 6 other Angiosarcoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03331250, a Phase 2 study of Angiosarcoma and Epithelioid Hemangioendothelioma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin
Primary Outcome
The ORR is defined as the percentage of patients who achieved a partial response or complete response by RECIST 1.1. Tumor imaging studies were completed using either CT (Computed Tomography) or MRI (Magnetic resonance imaging). The modality chosen for any individual patient was the same from baseline until the end of their time on study. Per RECIST v 1.1, complete response (CR) is defined as the disappearance of all target lesions and the reduction in any pathological lymph nodes in short axis
Conditions Studied
Interventions
- DRUG Eribulin
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2026-02-01 |
| Phase | Phase 2 |
What the registry record for NCT03331250 still lists
NCT03331250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,092-participant average among 6 other Angiosarcoma trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Angiosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Eribulin is the first listed.
NCT03331250 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03331250 about?
NCT03331250 is a clinical study titled "Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)". This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin
What is the current status of trial NCT03331250?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2018-01-18. Estimated completion is 2026-02-01.
What conditions does trial NCT03331250 study?
This clinical trial studies the following conditions: Angiosarcoma, Epithelioid Hemangioendothelioma.
What interventions are being tested in trial NCT03331250?
The interventions under investigation include: Eribulin (DRUG).
Who is sponsoring clinical trial NCT03331250?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03331250 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angiosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
RECRUITING · Phase 2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RECRUITING · Phase 1
-
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI